Roche Plans on Being in the Thick of Heating Immunotherapy Market

During a recent interview, Roche Chief Executive Severin Schwan indicated that the company would likely continue its focus on smaller-scale deal making.  The company will continue to focus on smaller acquisitions of “innovative companies” such as its recent purchase of Intermune.  “We have to be very consistent in our approach to M&A,” Schwan noted in an interview with the Wall Street Journal.

What the executive also addressed in that interview was the emerging area of immunotherapy—a space which Roche reportedly plans on moving five experimental drugs into clinical trial this year.  With companies such as Bristol-Myers Squibb, Merck and AstraZeneca all developing new therapies in this space, the competition has become intense.  Some analysts project that the industry as a whole could be worth as much as $35 billion annually in the future. 

Schwan believes this race will be decided by those with an edge in R&D.  “The winners and losers in the long term, I am absolutely sure, will be [decided by] those who do the clever combinations,” he told the newspaper. 

We’ll have more on the latest in immunogenicity at the 15^th Annual Immunogenicity for Biotherapeutics event. Join us October 20-22 in Boston, MA. Download the agenda to see what’s on tap.

SAVE $100. Register here and use code XP1938BLOG

Don’t miss a thing. Sign up for our email updates

Follow us on Twitter

Join us on LinkedIn

Share this article with your social network, just click below to share now!

Share |

The Updated 2012 Immunogenicity for Biotherapeutics Agenda is Available for Download

The updated brochure for the 13th Annual Immunogenicity for Biotherapeutics conference is now available. This year’s program offers something for everyone, from the most highly specialized immunochemists to scientists just starting their assay design and interpretation work. As the largest and longest-running conference devoted to designing safer molecules and reliable assays, no other event provides more cutting edge scientific insights.

Over 40 Immunogenicity experts address the four most important challenges facing pharmaceutical scientists today. Their case studies will help you:
• Predict Immunogenicity through a Better Understanding of its Underlying Causes
• Plan and Confirm Improvements in Clinical Assay Design
• Prevent Immunogenicity through Advances in Protein Engineering and Tolerance Induction
• Prepare for Breakthroughs in Immunogenicity Considerations for Biosimilars and Biobetters

Immunogenicity for Biotherapeutics is taking place April 17-19, 2012.  For more information on the event and the updated program, download the brochure here.

Share this article with your social network, just click below to share now!

Share |

Immunogenicity for Biotherapeutics 2010: Hear Case Studies from Amgen, Eli Lilly, & Pfizer

The 11th Annual Immunogenicity for Biotherapeutics convenes the industry’s leading experts and scientists to discuss updates on emerging regulatory updates, new assay development and validation strategies, novel and advanced case studies, and more to help your company conserve time and money so you weather the storm in today’s economy. Join 100+ colleagues to hear the latest immunogenicity techniques and learn how to accelerate approvals through the adoption of innovative scientific methods that deliver validated immunogenicity data.

→ Are you confident you are managing drug interference effectively?
Many consider drug interference as one of the toughest challenges in immunogenicity testing. Hear case studies from Amgen, Merrimack Pharmaceuticals, and Human Genome Sciences as these scientists share method validation techniques and lessons learned for handling drug interference with the diversity of therapeutic products in development.

→ Can you accurately evaluate the downstream impact of your immunogenicity data and establish clinical relevance for overall study interpretation?
Hear case studies from Eli Lilly and Biogen Idec on how to handle complicated immunogenicity assessments and the overall impact of these results upon clinical studies. Be ready to share your own lessons learned and ask questions of industry colleagues regarding strategies and solutions for data interpretation and establishing clinical relevance.

→ Do you need clarity on the induction of immunological tolerance to proteins?
To achieve the full potential of biologicals as therapeutic products, alternative approaches for eliminating immunogenicity are essential. Spend an afternoon with experts from Pfizer, State University of NY at Buffalo, Genzyme, and the University School of Medicine to discuss the details and challenges for tolerance induction to therapeutic proteins.

Join these sessions and many more at the longest running and the largest Immunogenicity event of the year. Visit our website to view the finalized agenda and to place your registration.

Share this article with your social network, just click below to share now!

Share |

Immunogenicity for Biotherapeutics 2010 Brochure Now Available!

Now in its 11th year, Immunogenicity for Biotherapeutics is THE longest running and THE largest event designed by and for the scientists who are driving progress and innovation in immunogenicity studies. The industry’s leading experts and scientists gather annually to discuss updates on emerging regulatory guidances, industry white papers, and exchange novel case studies and technology dedicated to drive forward the science, as well as, the discovery of solutions to the year’s top immunogenicity challenges.

Join us for THE immunogenicity event of the year to collaborate with the Elite Scientific Community Driving Innovation in Immunogenicity Screening and Characterization Strategies and Pushing Forward Regulatory Standardization and Global Best Practices.

We look forward to welcoming you April 26-28 in San Francisco. Download the brochure here. If you would like to join a community of others who focus on Immunogenicity, join the Immunogenicity for Biotherapeutics LinkedIn Group here.

Share this article with your social network, just click below to share now!

Share |